Krabbe disease, or globoid cell leukodystrophy, is an autosomal recessive disease caused by a deficiency of the lysosomal enzyme galactocerebrosidase (GALC). 1 Galactocerebroside and its toxic by-product psychosine accumulate in multinucleated macrophages (globoid cells) causing a progressive loss of myelin and secondary neuronal loss in the central and peripheral nervous system. Typically, an onset in infancy leads to delay in achieving motor milestones by 9 months followed by seizures, spasticity, blindness and progressive cognitive decline until death by the age of 2 years. Late-onset Krabbe disease occurs in early childhood or adulthood, and usually presents with a progressive spasticity, ataxia and subtle cognitive impairment, leading to death in early adulthood. 2 Standard myeloablative allogeneic haematopoietic stem cell transplantation (HSCT) has been demonstrated to correct the metabolic defect 3 in Krabbe disease, albeit with significant associated morbidity. Donor-derived monocytemacrophages with normal GALC repopulate the glial cells of the nervous system, providing a microenvironment with normal metabolic activity. Within the last 5 years, reducedintensity HSCT has proven to be safe and efficacious in a variety of haematological and non-haematological malignancies with significantly reduced toxicity. 4 Here, we report a successful case of reduced-intensity transplantation performed for late-onset globoid cell leukodystrophy.
A 24-year-old woman had been developmentally normal until 3 years of age when recurrent falls and clumsiness eventually led to a diagnosis of mild 'cerebral palsy'. From the age of 20, she developed dizzy spells, progressive leg stiffness and poor balance and coordination. Her mood was elevated with marked emotional lability. Brain magnetic resonance imaging showed moderate periventricular lesions and a diagnosis of multiple sclerosis was performed. Within 3 years, she required assistance to walk across a room, and was being cared for at home by her parents. Tests of coordination revealed moderate upper limb and marked lower limb ataxia. Repeat brain magnetic resonance imaging showed a confluence of white matter lesions. CSF protein was elevated at 660 mg/l (o450 mg/l) but no cellular or biochemical markers of inflammation were detected.
Galactocerebrosidase activity was 0.05 nmol/h/mg white cell protein (0.3-5.5), confirming the diagnosis of Krabbe disease. Neuropsychological testing demonstrated some cognitive impairment with a full-scale IQ of 90 (Premorbid IQ based on National Adult Reading Test 106) and selective deficits on measures of verbal memory (word-list recall following distraction and delayed story recall) and executive functions (verbal fluency, cognitive estimates), consistent with fronto-temporal lobe dysfunction. Family studies revealed a mildly affected female sibling (GALC 0.11) and an unaffected female sibling (GALC 0.98) who was fortuitously human leucocyte antigen (HLA) matched.
Given the fairly rapid neurological decline and following a fully informed discussion with the patient and her family, a decision was taken to proceed with a reduced-intensity allogeneic HSCT. Conditioning comprised fludarabine 30 mg/m 2 i.v. day À9 to day À5, oral busulphan 4 mg/kg/ day day À3 to day À2 and alemtuzumab (CAMPATH-1 H) 20 mg i.v. day À5 to dayÀ1, with cyclosporine and methotrexate for post transplant graft-versus-host disease (GVHD) prophylaxis. Cyclosporine was delivered 1.5 mg/ kg i.v. every 12 h from day À1 titrated to plasma trough levels of 150-200 ng/l. Oral cyclosporine was substituted when a good oral intake was achieved, and was rapidly tapered from day þ 56 in view of the absence of GVHD. Methotrexate was administered at a dose of 10 mg/m 2 i.v. once daily on days þ 1, þ 3, þ 6 and þ 12. Peripheral blood stem cells containing 14.1 Â 10 6 /kg CD34 þ cells from her HLA-matched sister were infused on day 0. Both donor and recipient were cytomegalovirus (CMV) seronegative. Post transplant course was unremarkable, there was no GVHD and engraftment was rapid with neutrophil engraftment (40.5 Â 10 9 /l) by day þ 13 and platelets (420 Â 10 9 /l) by day þ 14. There were no significant post transplant infectious complications.
Galactocerebrosidase level on day þ 393 was normalized at 0.68 nmol/h/mg white cell protein (0.3-5.5), and a recent repeat GALC level at 84 months post transplant remained at a level of 0.58 nmol/h/mg. In addition, donor-recipient chimerism was assessed with full donor chimerism confirmed on day þ 513 and maintained 84 months post-HSCT. Repeat magnetic resonance imaging scan of the head performed at 84 months post-HSCT confirmed no progression in the periventricular white matter lesions when compared with the pre-HSCT baseline scans.
At 84 months post-allograft, her coordination, balance and mobility are markedly improved such that she can walk unaided and live independently. Apart from developing thyrotoxicosis at 24 months post transplant requiring treatment with carbimazole and propanolol, she reports no new neurological symptoms with continued functional improvement.
In this case, reduced-intensity conditioning HSCT in late-onset Krabbe disease has resulted in the normalization of peripheral blood white cell GALC levels, arrest of disease progression and a significant improvement in neurological disability. Following HSCT in adult mice donor marrow, derived microglia and astroglia can be identified in the brain. Furthermore, HSCT in the GALCdeficient 'twitcher' mouse model of Krabbe disease results in the clearance of globoid cells, a milder neurological phenotype and increased survival. It seems likely that GALC competent donor microglia and astroglia are able to metabolize galactocerebroside in the brain, permitting remyelination and preventing further neuronal loss.
Escolar et al. 5 recently reported on the use of a myeloablative protocol with umbilical cord blood from unrelated donors for treatment of infantile Krabbe disease, with favourable engraftment and restoration of peripheral enzyme levels. While similarly encouraging results have been reported in late-onset Krabbe cases, 3 the use of myeloablative doses of chemoradiotherapy conditioning prior to stem cell infusion may cause significant morbidity. Reduced-intensity conditioning regimens depend heavily on intensive immunosuppression to permit donor engraftment, with an improved toxicity profile and minimal transplant-related morbidity. 4 Alemtuzumab is a monoclonal anti-CD52 antibody that induces marked depletion of T and B lymphocytes as well as dendritic cells of both donor and recipient, promoting donor engraftment with low incidence of GVHD. 6 While use of alemtuzumab-based reduced-intensity conditioning regimens is associated with an increased relapse rate in haematological malignancies, in non-malignant disorders a graft-versus-malignancy effect is of no benefit to the recipient and intensely immunosuppressive protocols may be advantageous. To our knowledge, this is the first described case of reduced-intensity conditioning HSCT for the successful treatment of lateonset Krabbe disease. Given the lower treatment-related toxicity, we suggest that reduced-intensity conditioning HSCT be considered as a feasible option for the treatment of these patients. 
